Short answer
MapLight Therapeutics, Inc. (MPLT) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). ATM facility authorizes up to $100 million in common-stock sales, providing MapLight flexible funding access.
MapLight Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- ATM facility authorizes up to $100 million in common-stock sales, providing MapLight flexible funding access
- Potential equity issuance creates shareholder dilution risk, depending on shares sold
- Leerink Partners commission up to 3.0% of gross sales, reducing net proceeds
- Company controls timing, with no obligation to sell and ability to suspend or terminate the agreement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MapLight Therapeutics, Inc. 8-K filings
Get the next MPLT 8-K as it lands
Follow MPLT for push alerts, or ask the research agent what this filing means.